Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The evolving treatment landscape of SCD

Clark Brown, MD, PhD, Aflac Cancer & Blood Disorders Center, Atlanta, GA, discusses advances in the field of sickle cell disease (SCD), discussing the mechanism of action of drugs such as voxelotor and GBT021601, and highlighting the promise of gene therapy and combination therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.


Consultancy: Global Blood Therapeutics, Imara, Novartis, Novo Nordisk; Research support: Global Blood Therapeutics, Forma Therapeutics, Imara, Novartis, Pfizer